Clinical and Molecular Correlates of Positron Emission Tomography (PET) With 89Zr-DFO-huJ591 in Metastatic Prostate Cancer

Inclusion Criteria

• •Metastatic Prostate Cancer Patients:
• •Adult male ≥ 18 years of age
• •Patients with histologically confirmed prostate cancer at MSKCC
• •Progressive disease manifest by either:
• •Imaging modalities:
• •Bone Scan: New osseous lesions on bone scan and/or
• •MRI or CT: An increase in measurable soft tissue disease or the appearance of new sites of disease.
• •OR
• •Biochemical progression:
• •At least 3 rising PSA values from a baseline that are obtained 1 week or more apart, or 2 measurements obtained 2 or more weeks apart. The increase over the range of values should be at least 25%.
• •Visible lesions by CT, bone scan, or MRI that are consistent with disease
• •Performance status of 60 or higher (Karnofsky scale) (Appendix B)
• •Ability to understand and willingness to sign a written informed consent document
• •Rising PSA Prostate Cancer Patients:
• •Adult male ≥18 years of age
• •Patients with histologically confirmed prostate cancer at MSKCC
• •Undergone radical prostatectomy
• •Detectable PSA (\>0.05 ng/mL) that rises on subsequent evaluation
• •Radiographic evaluation involving bone imaging and cross sectional imaging of at least the pelvis that is negative or equivocal for metastatic disease
• •Performance status of 60 or higher (Karnofsky scale) (Appendix B)
• •Ability to understand and willingness to sign a written informed consent document